Related Experiment Videos
Urinary L-valyl proline in patients with aortic aneurysms
J R Cohen1, T A Stein, A Dietzek
1Department of Surgery, Long Island Jewish Medical Center, New Hyde Park, New York 11042.
Surgery, Gynecology & Obstetrics
|June 1, 1989
Summary
Urinary L-valyl proline (LVP) levels are elevated in patients with aortic aneurysmal disease, indicating altered elastin metabolism. This biomarker may help detect infrarenal aortic pathologic findings.
Area of Science:
- Biochemistry
- Vascular Biology
- Metabolomics
Background:
- Elastin metabolism alterations are implicated in infrarenal aortic diseases.
- The balance between aortic elastase and antiprotease activity influences disease phenotype.
- L-valyl proline (LVP), a specific elastin peptide, can be measured in urine.
Purpose of the Study:
- To investigate if urinary LVP quantitation can detect systemic elastin metabolism changes in patients with different infrarenal aortic diseases.
- To correlate urinary LVP levels with aortic elastase and antiprotease activity.
Main Methods:
- Urine samples were collected from patients categorized into five groups: control, occlusive aortic disease, elective abdominal aortic aneurysms (AAA), ruptured AAA, and multiple aneurysms.
- Urinary LVP was measured using high-performance liquid chromatography.
- Urine LVP values were correlated with aortic elastase and antiprotease activity.
Main Results:
- Urinary LVP was significantly higher in patients with multiple aneurysms compared to all other groups.
- Patients with elective AAA showed significantly higher urinary LVP than those with occlusive disease and controls.
- Urinary LVP levels increased significantly with elevated aortic elastase and antiprotease activity.
Conclusions:
- Systemic elastin metabolism is altered in patients with aortic aneurysmal disease.
- Urinary LVP serves as a potential biomarker for detecting alterations in elastin metabolism associated with infrarenal aortic pathologies.